Diagnosis and treatment of human dormancy-related sequellae

A method for diagnosing a human dormancy syndrome-related sequel in a human, comprising the steps of:

• (a) determining the presence of a finding selected from the group consisting of:
• an elevated level of:
• fungal or bacterial DNA, Chlamydia, Mycoplasma, alpha 2-macroglobulin, alpha-fetoprotein, angiotensin II, Bcl-2, Bcl-XL c-fos, c-jun levels and/or ACE activity, CGRP, calsequestrin, CEA, catalase cathespin B, cIAP-2, connexin 43, CRF, COX-2 activity, d-dimer, endothelin-1, endotoxin, enkephalin, epithelial growth factor, FADD, fas ligand and/or the fas/APO 1 ratio, FLIP, gap junction activity, gastrin, ghrelin, glutathione peroxidase, FABP, heme oxygenase-1, hormone-sensitive lipase, HSP70, HIF-1, ICAM-1, IGF-1, IL-6, JNK, kallikrein, kinin, lipoxygenase, MAPK, Mcl-1, activation of the moesin-ezrin system, neuropeptide Y, neurotensin, NF kappa B, pancreatic triglyceride lipase, PDK, peptide YY, prolactin, prostcyclin, PGE2, protein kinase C, resistin, rT3, serine protease, substance P, superoxide dismutatse, survivin, TNF alpha, tyrosine hydroxylase, UCP2 & 3 activity, VIP, vasopressin or VEGF or a decreased level of alpha-1 antitrypsin, antithrombin III, apolipoprotein, ascorbic acid, Bax, Bid and/or Bad, C1-esterase inhibitor, caspase, caveolin-1, cystatin, cytochrome-c oxidase, dopamine, Factor V, fT3, glyceraldehyde-3-phosphate dehydrogenase activity, GSH/GSSG ratio, IGFBP, junB, melatonin levels, Na/K ATPase activity, nitric oxide, orexin-A, hypocretin-1, altered oxytocin levels, decreased p53, PARP, PPAR gamma, ROCK-2, secretin, serotonin or TRAIL activity;
• (b) calculating the ratio of rT3/fT3, wherein said ratio is above about 4;
• and
• (c) determining the presence of one or more findings selected from the group consisting of persistent fatigue, cognitive impairment, weight gain, depression, alopecia, constipation, insomnia, sleep apnea, loss of libido, cold intolerance, exercise intolerance, addiction to stimulants, history of Raynaud's Syndrome, dislipidemia, atherosclerosis, syndrome X, peripheral vascular disease, type II diabetes, dementia, demyelinating disease, muscle tension headache, migraine, fibrocystic breast disease, cancer, breast cancer, prostate cancer, ovarian cancer, cholelithiasis, pulmonary artery hypertension, pulmonary fibrosis, COPD, asthma, systemic hypertension, infertility, fibromyalgia, chronic fatigue syndrome, chronic pain, obesity, lupus, scleroderma, rheumatoid arthritis, sarcoidosis, vasculitis, myositis, ankylosising spondylitis, psoriatic arthritis, reactive arthritis, Reiter's syndrome, Becet's, polymyalgia rheumatica, viral, bacterial and/or fungal infection, septic shock, osteopenia, osteoporosis, pneumonia, narcolepsy, hypertension, liver disease, esophageal dysmotility, inflammatory bowel disease, renal disease, Parkinson's disease, coma, impaired stage 4 sleep, irritable bowel syndrome, elevated sympathetic nervous system activity, dysregulated HPA, mitochondrial impairment, compulsivity, hypervigilance, dissociation, impaired natural killer cell activity, elevated CSF substance P levels, blunted growth hormone response during provocation testing, orthostatic hypotension and altered cerebral blood flow.

A method for treating cancer in a patient, comprising:

• (a) administering amoxicillin or doxycycline (100 mg/2×/day) or minocyn (100 mg 2×/day) for 2 weeks;
• then
• (b) along with the antibiotic of step (a), administering zithromax (250-500 mg 3×/week) or ketek (100 mg 2×/day) for 2 weeks;
• then
• (c). administering metronidazole (500 mg 2×/day) for 5 days;
• then
• (d) ceasing treatment with metronidazole for two weeks while maintaining steps (a) & (b) above);
• then
• (e) administering metronidazole (500 mg 2×/day) for 5 days on, 2 weeks off until symptoms of endotoxemia decrease;
• then
• (f) administering metronidazole at a dose of 1000 mg 2×/day or 2000 mg 2×/day untiltumor cell death occurs.